<DOC>
	<DOCNO>NCT02665364</DOCNO>
	<brief_summary>The safety immunogenicity IFN-Kinoid ( IFN-K ) evaluate phase I clinical study conduct subject SLE . Preliminary result promise . The principal aim present study confirm neutralization interferon gene signature clinical efficacy IFN-K subject SLE . In addition , immune response safety elicit IFN-K also evaluate .</brief_summary>
	<brief_title>Study IFN-K Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Has diagnosis SLE accord current ACR criterion ( 4 11 ACR criterion ) Has SLEDAI2K ≥ 6 Has least 1 BILAG A and/or least 2 BILAG B Has positive IFN gene signature RTqPCR Has ANA ≥ 1:160 and/or antidsDNA antibody ≥ 7.0 IU/mL Currently receive least one treatment SLE Has active , severe lupus nephritis define either immediate need cyclophosphamide treatment renal BILAG A Has active , severe , neuropsychiatric SLE , define neuropsychiatric BILAG A Has treat corticosteroid ( CS ) dose &gt; 20 mg prednisone equivalent/day &gt; 7 consecutive day Is currently receive receive pulse dose CS ( ≥ 250 mg prednisone equivalent/day ) Has receive potent immunosuppressive drug Has receive abatacept , sifalimumab , rontalizumab , anifrolumab , belimumab , TNF antagonists another registered investigational biological therapy Has receive antiBcell therapy ( e.g. , rituximab , epratuzumab ) Has frequent recurrence oral genital herpes simplex lesion Is high risk significant infection and/or current sign symptom infection entry receive intravenous antibiotic Has receive live vaccine Has use investigational nonregistered product investigational nonregistered vaccine Is highrisk human papilloma virus ( HPV ) positive rRTqPCR cervical swab Has cytological abnormality ≥ HSIL cervical swab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>